Intravenous delivery of enzalutamide based on high drug loading multifunctional graphene oxide nanoparticles for castration-resistant prostate cancer therapy

Enzalutamide (Enz) has shown limited bioavailability via oral administration. Castration-resistant prostate cancer (CRPC) is frequent among patients receiving 18 –24 months of androgen deprivation therapy. The ...

Source: Journal of Nanobiotechnology - March 18, 2020 Category: Nanotechnology Authors: Wenjun Jiang, Jiyuan Chen, Chunai Gong, Yuanyuan Wang, Yuan Gao and Yongfang Yuan Tags: Research Source Type: research